JP7249287B2 - Ｔ細胞受容体シグナル伝達を阻害または調節することによって、ｔ細胞枯渇を処置する方法 - Google Patents

Ｔ細胞受容体シグナル伝達を阻害または調節することによって、ｔ細胞枯渇を処置する方法 Download PDF

Info

Publication number
JP7249287B2
JP7249287B2 JP2019553214A JP2019553214A JP7249287B2 JP 7249287 B2 JP7249287 B2 JP 7249287B2 JP 2019553214 A JP2019553214 A JP 2019553214A JP 2019553214 A JP2019553214 A JP 2019553214A JP 7249287 B2 JP7249287 B2 JP 7249287B2
Authority
JP
Japan
Prior art keywords
car
cells
domain
acid sequence
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019553214A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020515259A (ja
JP2020515259A5 (https=
Inventor
リン，レイチェル
マッコール，クリスタル
ジェー． ワンドレス，トム
ウェバー，エヴァン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of JP2020515259A publication Critical patent/JP2020515259A/ja
Publication of JP2020515259A5 publication Critical patent/JP2020515259A5/ja
Priority to JP2022193805A priority Critical patent/JP7674328B2/ja
Application granted granted Critical
Publication of JP7249287B2 publication Critical patent/JP7249287B2/ja
Priority to JP2024200383A priority patent/JP2025026930A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4256—Tumor associated carbohydrates
    • A61K40/4258—Gangliosides, e.g. GM2, GD2 or GD3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases [EC 2.]
    • C12N2501/727—Kinases (EC 2.7.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2019553214A 2017-03-31 2018-03-30 Ｔ細胞受容体シグナル伝達を阻害または調節することによって、ｔ細胞枯渇を処置する方法 Active JP7249287B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022193805A JP7674328B2 (ja) 2017-03-31 2022-12-02 Ｔ細胞受容体シグナル伝達を阻害または調節することによって、ｔ細胞枯渇を処置する方法
JP2024200383A JP2025026930A (ja) 2017-03-31 2024-11-18 Ｔ細胞受容体シグナル伝達を阻害または調節することによって、ｔ細胞枯渇を処置する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762479930P 2017-03-31 2017-03-31
US62/479,930 2017-03-31
PCT/US2018/025459 WO2018183888A2 (en) 2017-03-31 2018-03-30 Methods of treating t cell exhaustion by inhibiting or modulating t cell receptor signaling

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022193805A Division JP7674328B2 (ja) 2017-03-31 2022-12-02 Ｔ細胞受容体シグナル伝達を阻害または調節することによって、ｔ細胞枯渇を処置する方法

Publications (3)

Publication Number Publication Date
JP2020515259A JP2020515259A (ja) 2020-05-28
JP2020515259A5 JP2020515259A5 (https=) 2021-04-08
JP7249287B2 true JP7249287B2 (ja) 2023-03-30

Family

ID=63677091

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2019553214A Active JP7249287B2 (ja) 2017-03-31 2018-03-30 Ｔ細胞受容体シグナル伝達を阻害または調節することによって、ｔ細胞枯渇を処置する方法
JP2019553220A Active JP7278961B2 (ja) 2017-03-31 2018-03-30 Ｔ細胞受容体のシグナル伝達を阻害するまたは調節することによってｔ細胞の疲弊を治療する方法
JP2022193805A Active JP7674328B2 (ja) 2017-03-31 2022-12-02 Ｔ細胞受容体シグナル伝達を阻害または調節することによって、ｔ細胞枯渇を処置する方法
JP2023011257A Pending JP2023055805A (ja) 2017-03-31 2023-01-27 Ｔ細胞受容体のシグナル伝達を阻害するまたは調節することによってｔ細胞の疲弊を治療する方法
JP2024123405A Pending JP2024153812A (ja) 2017-03-31 2024-07-30 Ｔ細胞受容体のシグナル伝達を阻害するまたは調節することによってｔ細胞の疲弊を治療する方法
JP2024200383A Pending JP2025026930A (ja) 2017-03-31 2024-11-18 Ｔ細胞受容体シグナル伝達を阻害または調節することによって、ｔ細胞枯渇を処置する方法

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2019553220A Active JP7278961B2 (ja) 2017-03-31 2018-03-30 Ｔ細胞受容体のシグナル伝達を阻害するまたは調節することによってｔ細胞の疲弊を治療する方法
JP2022193805A Active JP7674328B2 (ja) 2017-03-31 2022-12-02 Ｔ細胞受容体シグナル伝達を阻害または調節することによって、ｔ細胞枯渇を処置する方法
JP2023011257A Pending JP2023055805A (ja) 2017-03-31 2023-01-27 Ｔ細胞受容体のシグナル伝達を阻害するまたは調節することによってｔ細胞の疲弊を治療する方法
JP2024123405A Pending JP2024153812A (ja) 2017-03-31 2024-07-30 Ｔ細胞受容体のシグナル伝達を阻害するまたは調節することによってｔ細胞の疲弊を治療する方法
JP2024200383A Pending JP2025026930A (ja) 2017-03-31 2024-11-18 Ｔ細胞受容体シグナル伝達を阻害または調節することによって、ｔ細胞枯渇を処置する方法

Country Status (7)

Country Link
US (3) US20200101108A1 (https=)
EP (2) EP3600323A4 (https=)
JP (6) JP7249287B2 (https=)
CN (3) CN118161496A (https=)
AU (3) AU2018243571B2 (https=)
CA (2) CA3057505A1 (https=)
WO (2) WO2018183842A1 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111699001A (zh) * 2017-12-07 2020-09-22 尤利乌斯·马克西米利安维尔茨堡大学 达沙替尼和其他酪氨酸激酶抑制剂对基因修饰的嵌合抗原受体t细胞的功能的控制和调节
WO2020092650A1 (en) * 2018-10-30 2020-05-07 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for modulating t cell exhaustion
CA3117978A1 (en) * 2018-11-08 2020-05-14 Juno Therapeutics, Inc. Methods and combinations for treatment and t cell modulation
CN120174005A (zh) 2019-02-13 2025-06-20 比姆医疗股份有限公司 具有用于修饰靶标序列中核碱基的腺苷脱氨酶碱基编辑器的经修饰的免疫细胞
EP3931216A4 (en) * 2019-03-01 2023-04-19 National University of Singapore MANIPULATED IMMUNE CELLS
CN110157680A (zh) * 2019-05-08 2019-08-23 浙江大学 提高嵌合抗原受体t细胞疗效和作用持久性的细胞培养方法
EP4008347B1 (en) * 2019-08-01 2025-04-30 Mie University GD2-BINDING MOLECULE
EP4034138A4 (en) 2019-09-27 2024-07-31 Beam Therapeutics, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIQUID CANCERS
GB202000934D0 (en) * 2020-01-22 2020-03-04 Ucl Business Ltd Engineered immune cells
CA3158133A1 (en) 2020-04-28 2021-11-04 Lyell Immunopharma, Inc. Methods for culturing cells
EP4159843A4 (en) * 2020-05-29 2024-07-31 Shanghai Juncell Therapeutics Co., Ltd. MEDIUM FOR SEEDING CELLS OF TUMOR INFILTRATING LYMPHOCYTES AND ITS APPLICATION
MX2022015764A (es) * 2020-06-19 2023-01-19 Chugai Pharmaceutical Co Ltd Molecula de union al antigeno anti-celulas t para usarse en combinacion con un inhibidor de angiogenesis.
KR20230074146A (ko) * 2020-09-24 2023-05-26 에프. 호프만-라 로슈 아게 T 세포 이중특이성 항체 관련 역효과의 예방 또는 완화
CA3196831A1 (en) 2020-09-25 2022-03-31 Beam Therapeutics Inc. Fratricide resistant modified immune cells and methods of using the same
JP2023549079A (ja) * 2020-10-30 2023-11-22 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 二重標的化キメラ抗原受容体
WO2022210487A1 (ja) * 2021-03-29 2022-10-06 タカラバイオ株式会社 抗原に特異的な受容体を発現する免疫細胞の製造方法
EP4071248A1 (en) 2021-04-07 2022-10-12 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Means and methods for enhancing receptor-targeted gene transfer
US20240238419A1 (en) * 2021-05-07 2024-07-18 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Method for constitutive malt1 protease activation
CN113533729B (zh) * 2021-06-15 2024-09-06 北京大学人民医院 一种鉴定aml患者骨髓中nk细胞耗竭的研究方法及其应用
JP2024525727A (ja) 2021-07-14 2024-07-12 ２セブンティ バイオ インコーポレイテッド 抗体由来の結合ドメインに融合した操作されたｔ細胞受容体
CN115677861B (zh) * 2021-07-29 2026-03-06 上海科技大学 一种泛素偶联修饰的嵌合抗原受体及免疫细胞
IL312204A (en) 2021-10-28 2024-06-01 Lyell Immunopharma Inc Methods for culturing cells expressing ror1-binding protein
IL312201A (en) 2021-10-28 2024-06-01 Lyell Immunopharma Inc Methods for culturing cells expressing c-jun
CA3255500A1 (en) 2022-04-08 2023-10-12 Regeneron Pharmaceuticals, Inc. MULTI-PART RECEIVERS AND SIGNALING COMPLEXES
AU2023292081A1 (en) * 2022-06-13 2025-01-09 The Regents Of The University Of California Improved glycan-dependent chimeric antigen receptor cells
GB202218144D0 (en) * 2022-12-02 2023-01-18 Univ Oxford Innovation Ltd Product
CN116121196B (zh) * 2022-12-23 2025-07-22 广州安捷生物医学技术有限公司 一种调控car-t细胞的方法与应用
WO2025221871A1 (en) * 2024-04-16 2025-10-23 The Trustees Of Columbia University In The City Of New York Expansion, propagation, and modulation of immune cell subsets by peptides

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016508518A (ja) 2013-02-15 2016-03-22 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア キメラ抗原受容体及びその使用方法
US20160272718A1 (en) 2015-03-17 2016-09-22 Chimera Bioengineering, Inc. Smart CAR Devices, DE CAR Polypeptides, Side CARs and Uses Thereof
JP2017508466A (ja) 2014-03-06 2017-03-30 ユーシーエル ビジネス ピーエルシー キメラ抗原受容体

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2210812C (en) 1995-01-16 2009-09-01 Nicholas Manolios T-cell affecting peptides
US20050070478A1 (en) 1996-06-11 2005-03-31 Northern Sydney Area Health Services T cell antigen receptor peptides
US20050113564A1 (en) 2003-11-05 2005-05-26 St. Jude Children's Research Hospital Chimeric receptors with 4-1BB stimulatory signaling domain
GB0523954D0 (en) 2005-11-24 2006-01-04 Ucb Celltech Bioassays
US9334330B2 (en) 2006-10-10 2016-05-10 Universite De Nantes Use of monoclonal antibodies specific to the O-acetylated form of GD2 ganglioside for the treatment of certain cancers
US8173792B2 (en) 2007-02-09 2012-05-08 The Board Of Trustees Of The Leland Stanford Junior University Method for regulating protein function in cells using synthetic small molecules
EP2664916B1 (en) 2007-04-02 2017-02-08 Acoustic Cytometry Systems, Inc. Method for manipulating a fluid medium within a flow cell using acoustic focusing
WO2012033885A1 (en) 2010-09-08 2012-03-15 Baylor College Of Medicine Immunotherapy of cancer using genetically engineered gd2-specific t cells
US9845362B2 (en) 2010-10-08 2017-12-19 The University Of North Carolina At Charlotte Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
CA2832540C (en) 2011-04-08 2020-09-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer
PL3892295T3 (pl) 2011-05-24 2023-07-24 BioNTech SE Zindywidualizowane szczepionki przeciwnowotworowe
ES2654060T3 (es) 2011-10-20 2018-02-12 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Receptores de antígenos quiméricos anti-CD22
CA2857687C (en) * 2011-12-02 2019-07-09 Stillwater Mining Company Quantitative precious metals recovery in the presence of interfering metals, salts, and ions
RU2766608C2 (ru) 2012-04-11 2022-03-15 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез Химерные антигенные рецепторы, нацеленные на антиген созревания b-клеток
WO2014055771A1 (en) 2012-10-05 2014-04-10 The Trustees Of The University Of Pennsylvania Human alpha-folate receptor chimeric antigen receptor
JP6647868B2 (ja) 2013-02-20 2020-02-14 ノバルティス アーゲー ヒト化抗ＥＧＦＲｖＩＩＩキメラ抗原受容体を用いたがんの処置
US9446105B2 (en) 2013-03-15 2016-09-20 The Trustees Of The University Of Pennsylvania Chimeric antigen receptor specific for folate receptor β
US9790282B2 (en) 2013-03-25 2017-10-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-CD276 polypeptides, proteins, and chimeric antigen receptors
EP3783098A1 (en) 2013-05-14 2021-02-24 Board Of Regents, The University Of Texas System Human application of engineered chimeric antigen receptor (car) t-cells
US9636340B2 (en) * 2013-11-12 2017-05-02 Ayyappan K. Rajasekaran Kinase inhibitors
WO2015179801A1 (en) * 2014-05-23 2015-11-26 University Of Florida Research Foundation, Inc. Car based immunotherapy
EP3169363A4 (en) 2014-07-16 2018-02-21 F. Hoffmann-La Roche AG Methods of treating cancer using tigit inhibitors and anti-cancer agents
TWI719942B (zh) 2014-07-21 2021-03-01 瑞士商諾華公司 使用ｃｄ３３嵌合抗原受體治療癌症
ES2878449T3 (es) * 2014-07-24 2021-11-18 2Seventy Bio Inc Receptores antigénicos quiméricos de BCMA
MX2017002205A (es) 2014-08-19 2017-08-21 Novartis Ag Receptor quimerico de antigeno (car) anti-cd123 para uso en el tratamiento de cancer.
WO2016061368A1 (en) 2014-10-15 2016-04-21 The Children's Hospital Of Philadelphia Compositions and methods for treating b-lymphoid malignancies
GB201500319D0 (en) * 2015-01-09 2015-02-25 Agency Science Tech & Res Anti-PD-L1 antibodies
WO2016134284A1 (en) * 2015-02-19 2016-08-25 University Of Florida Research Foundation, Inc. Chimeric antigen receptors and uses thereof
GB201514328D0 (en) 2015-08-12 2015-09-23 Sigmoid Pharma Ltd Compositions
JP7653759B2 (ja) 2016-01-20 2025-03-31 フェイト セラピューティクス，インコーポレイテッド 養子免疫療法における免疫細胞調節のための組成物および方法
KR20230148844A (ko) * 2016-03-29 2023-10-25 유니버시티 오브 써던 캘리포니아 암을 표적하는 키메라 항원 수용체
CN109715808A (zh) * 2016-04-15 2019-05-03 诺华股份有限公司 用于选择性蛋白质表达的组合物和方法
EP3548049A4 (en) 2016-12-05 2020-07-22 Fate Therapeutics, Inc. COMPOSITIONS AND METHODS FOR MODULATION OF IMMUNE CELLS IN ADOPTIVE IMMUNOTHERAPIES
CN111699001A (zh) 2017-12-07 2020-09-22 尤利乌斯·马克西米利安维尔茨堡大学 达沙替尼和其他酪氨酸激酶抑制剂对基因修饰的嵌合抗原受体t细胞的功能的控制和调节
WO2020092650A1 (en) * 2018-10-30 2020-05-07 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for modulating t cell exhaustion

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016508518A (ja) 2013-02-15 2016-03-22 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア キメラ抗原受容体及びその使用方法
JP2017508466A (ja) 2014-03-06 2017-03-30 ユーシーエル ビジネス ピーエルシー キメラ抗原受容体
US20160272718A1 (en) 2015-03-17 2016-09-22 Chimera Bioengineering, Inc. Smart CAR Devices, DE CAR Polypeptides, Side CARs and Uses Thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Nat. Med.，2015年06月，Vol.21, No.6, 581-590，pp.1-27
PLoS One，2013年06月06日，Vol.8, No.6, e65519，pp.1-10
Sci. Rep.，Vol.6, No.18950，2016年01月11日，pp.1-7

Also Published As

Publication number Publication date
JP2024153812A (ja) 2024-10-29
JP2020515581A (ja) 2020-05-28
US20240293461A1 (en) 2024-09-05
US20200101108A1 (en) 2020-04-02
EP3600323A4 (en) 2020-11-11
JP7278961B2 (ja) 2023-05-22
JP2025026930A (ja) 2025-02-26
JP2023025187A (ja) 2023-02-21
CA3057372A1 (en) 2018-10-04
JP2020515259A (ja) 2020-05-28
AU2018243571B2 (en) 2024-03-07
CA3057505A1 (en) 2018-10-04
CN110582280A (zh) 2019-12-17
WO2018183888A3 (en) 2018-11-08
EP3600323A1 (en) 2020-02-05
CN110603044A (zh) 2019-12-20
WO2018183888A2 (en) 2018-10-04
JP2023055805A (ja) 2023-04-18
EP3600357A4 (en) 2021-01-06
AU2024203919A1 (en) 2024-07-04
AU2018243664A1 (en) 2019-10-17
AU2018243571A1 (en) 2019-10-17
WO2018183842A1 (en) 2018-10-04
AU2018243664B2 (en) 2024-02-01
US11938153B2 (en) 2024-03-26
JP7674328B2 (ja) 2025-05-09
CN110582280B (zh) 2024-03-19
US20210032363A1 (en) 2021-02-04
CN110603044B (zh) 2024-11-05
EP3600357A2 (en) 2020-02-05
CN118161496A (zh) 2024-06-11

Similar Documents

Publication Publication Date Title
JP7674328B2 (ja) Ｔ細胞受容体シグナル伝達を阻害または調節することによって、ｔ細胞枯渇を処置する方法
US20240018271A1 (en) Enhancing Activity of CAR T Cells by Co-Introducing a Bispecific Antibody
US10800840B2 (en) Compositions and methods for generating a persisting population of T cells useful for the treatment of cancer
JP7291396B2 (ja) 融合タンパク質を用いたｔｃｒの再プログラミングのための組成物及び方法
JP7109789B2 (ja) 融合タンパク質を使用したｔｃｒの再プログラム化のための組成物及び方法
JP7372728B2 (ja) 改変ｔ細胞に関する方法および組成物
JP2023052446A (ja) 融合タンパク質を用いてｔ細胞受容体をリプログラミングするための組成物及び方法
JP6482461B2 (ja) 投与に関する形質導入ｔ細胞の適合性の評価方法
JP2018518978A (ja) キメラ抗原受容体（ｃａｒ）療法のためのｔ細胞の供給源としての骨髄浸潤リンパ球（ｍｉｌ）
US20210269501A1 (en) Compositions and methods of nkg2d chimeric antigen receptor t cells for controlling triple-negative breast cancer
JP7764035B2 (ja) 細胞治療の方法
HK40040144A (en) Enhancing activity of car t cells by co-introducing a bispecific antibody

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210225

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210225

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220408

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220802

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221202

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20221202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20221202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20221202

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20221222

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20230110

C272 Notice of ex officio correction

Free format text: JAPANESE INTERMEDIATE CODE: C272

Effective date: 20230110

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230221

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230317

R150 Certificate of patent or registration of utility model

Ref document number: 7249287

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150